RRC ID 62733
著者 Takeda H, Okada M, Suzuki S, Kuramoto K, Sakaki H, Watarai H, Sanomachi T, Seino S, Yoshioka T, Kitanaka C.
タイトル Rho-Associated Protein Kinase (ROCK) Inhibitors Inhibit Survivin Expression and Sensitize Pancreatic Cancer Stem Cells to Gemcitabine.
ジャーナル Anticancer Res
Abstract BACKGROUND:Targeting pathways regulating survivin expression, which has been implicated in multidrug resistance of cancer cells, is a promising strategy to overcome cancer chemoresistance. To date, the role of rho-associated protein kinases (ROCKs) in survivin expression remains largely unknown.
MATERIALS AND METHODS:The effects of ROCK inhibitors Y-27632 and fasudil on survivin expression and cell viability were determined by immunoblot analysis and dye exclusion, respectively, in PANC-1 CSLC, a cancer stem cell line derived from a serum-cultured, gemcitabine-sensitive pancreatic cancer cell line, PANC-1.
RESULTS:siRNA-mediated knockdown of survivin revealed that the gemcitabine resistance of PANC-1 CSLC was dependent on survivin expression. Both Y-27632 and fasudil, reduced survivin expression in PANC-1 CSLC cells and sensitized them to gemcitabine. ROCK inhibition also reduced survivin expression in various other human cancer cell lines.
CONCLUSION:Small molecule inhibitor-mediated targeting of ROCK may be a viable strategy to overcome cancer chemoresistance through down-regulation of survivin.
巻・号 36(12)
ページ 6311-6318
公開日 2016-12-1
DOI 10.21873/anticanres.11227
PII 36/12/6311
PMID 27919951
MeSH Antimetabolites, Antineoplastic / pharmacology* Deoxycytidine / analogs & derivatives* Deoxycytidine / pharmacology Drug Synergism Gemcitabine Humans Inhibitor of Apoptosis Proteins / metabolism* Neoplastic Stem Cells / drug effects* Neoplastic Stem Cells / metabolism Pancreatic Neoplasms / metabolism Pancreatic Neoplasms / pathology* Protein Kinase Inhibitors / pharmacology* Survivin rho-Associated Kinases / antagonists & inhibitors*
IF 1.994
リソース情報
ヒト・動物細胞 A549(RCB0098)